MONJUVI Market Summary

Key Factors Driving MONJUVI Growth

1. Expansion into follicular lymphoma (FL) significantly enlarges the commercial opportunity:

The most important recent growth driver is the June 2025 FDA approval of MONJUVI in combination with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma. The approval was based on the Phase III inMIND study of 548 patients, in which adding tafasitamab reduced the risk of progression, relapse, or death by 57% versus lenalidomide plus rituximab alone (HR 0.43; p<0.0001). Median PFS was 22.4 months versus 13.9 months. This moved tafasitamab beyond its original DLBCL market into a substantially broader FL treatment population.

2. Strong Phase III efficacy supports adoption of the new FL regimen:

The inMIND results provide robust clinical evidence for the expanded indication. The trial was conducted across 210 centers in North America, Europe and Asia-Pacific, improving the relevance of the evidence across different healthcare settings. Importantly, the safety profile was broadly comparable between the tafasitamab and control groups; the most frequent adverse events included neutropenia and diarrhea. The peer-reviewed Lancet publication concluded that tafasitamab plus lenalidomide and rituximab produced a statistically significant and clinically meaningful PFS improvement. This evidence can support physician uptake and treatment-line adoption in relapsed/refractory FL.

3. Rapid commercial contribution from the FL launch:

Incyte reported that MONJUVI/MINJUVI generated $144.6 million in 2025, up from $119.3 million in 2024, representing approximately 21% growth. Importantly, Incyte attributed the 2025 increase primarily to the approval and launch of tafasitamab in FL in the middle of 2025. By Q4 2025, quarterly sales had reached $42 million, a 28% sequential increase, demonstrating that the new indication was already contributing materially to the franchise.

4. Momentum continued strongly into 2026:

The growth trajectory accelerated in the first half of 2026. MONJUVI/MINJUVI generated $53.7 million in Q2 2026, compared with $31.1 million in Q2 2025, representing 72% year-over-year growth. First-half 2026 sales reached $102.9 million, versus $60.7 million during the same period of 2025, a 67% increase. Incyte specifically cited increased demand for MONJUVI/MINJUVI in FL as a contributor to its broader Hematology & Oncology growth.

5. International expansion provides an additional revenue runway:

Tafasitamab is marketed as MONJUVI in the U.S. and MINJUVI in international markets. Incyte's 2026 filings state that growth in MONJUVI/MINJUVI and other hematology products reflected continued strong U.S. uptake and entry into new markets outside the U.S. The European/international commercial footprint therefore provides an additional source of growth beyond U.S. FL adoption.

MONJUVI Recent Developments

In May 2026, Incyte announced positive results from the pivotal Phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (MONJUVI/MINJUVI), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL).

“MONJUVI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of MONJUVI for approved indication like Diffuse large B cell lymphoma and Follicular lymphoma; as well as potential indication like Marginal zone B-cell lymphoma, Autoimmune haemolytic anaemia, B-cell lymphoma, Chronic lymphocytic leukaemia, and Haematological malignancies in the 7MM. A detailed picture of MONJUVI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the MONJUVI for approved and potential indications. The MONJUVI market report provides insights about MONJUVI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current MONJUVI performance, future market assessments inclusive of the MONJUVI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of MONJUVI sales forecasts, along with factors driving its market.

MONJUVI Drug Summary

MONJUVI is a humanized Fc-modified immunotherapy developed by MorphoSys, now part of Novartis, for the treatment of certain patients with B-cell malignancies. It is a CD19-directed monoclonal antibody designed to target CD19, a surface antigen expressed on B cells, including malignant B cells. Tafasitamab enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) through its modified Fc region, helping recruit immune effector cells to destroy targeted cancer cells. The drug is administered through intravenous infusion and was developed for use in combination with other anticancer therapies. The report provides MONJUVI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the MONJUVI Market Report

The report provides insights into:

• A comprehensive product overview including the MONJUVI MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma and Follicular lymphoma; as well as potential indication like Marginal zone B-cell lymphoma, Autoimmune haemolytic anaemia, B-cell lymphoma, Chronic lymphocytic leukaemia, and Haematological malignancies.
• Elaborated details on MONJUVI regulatory milestones and other development activities have been provided in MONJUVI market report.
• The report also highlights MONJUVI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The MONJUVI market report also covers the patents information, generic entry and impact on cost cut.
• The MONJUVI market report contains current and forecasted MONJUVI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The MONJUVI market report also features the SWOT analysis with analyst views for MONJUVI in approved and potential indications.

Methodology

The MONJUVI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MONJUVI Analytical Perspective by DelveInsight

• In-depth MONJUVI Market Assessment

This MONJUVI sales market forecast report provides a detailed market assessment of MONJUVI for approved indication like Diffuse large B cell lymphoma and Follicular lymphoma; as well as potential indication like Marginal zone B-cell lymphoma, Autoimmune haemolytic anaemia, B-cell lymphoma, Chronic lymphocytic leukaemia, and Haematological malignancies in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted MONJUVI sales data uptil 2034.

• MONJUVI Clinical Assessment

The MONJUVI market report provides the clinical trials information of MONJUVI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

MONJUVI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

MONJUVI Market Potential & Revenue Forecast

• Projected market size for the MONJUVI and its key indications
• Estimated MONJUVI sales potential (MONJUVI peak sales forecasts)
• MONJUVI Pricing strategies and reimbursement landscape

MONJUVI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• MONJUVI Market positioning compared to existing treatments
• MONJUVI Strengths & weaknesses relative to competitors

MONJUVI Regulatory & Commercial Milestones

• MONJUVI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

MONJUVI Clinical Differentiation

• MONJUVI Efficacy & safety advantages over existing drugs
• MONJUVI Unique selling points

MONJUVI Market Report Highlights

• In the coming years, the MONJUVI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The MONJUVI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MONJUVI’s dominance.
• Other emerging products for Diffuse large B cell lymphoma and Follicular lymphoma; as well as potential indication like Marginal zone B-cell lymphoma, Autoimmune haemolytic anaemia, B-cell lymphoma, Chronic lymphocytic leukaemia, and Haematological malignancies are expected to give tough market competition to MONJUVI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MONJUVI in approved and potential indications.
• Analyse MONJUVI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted MONJUVI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of MONJUVI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of MONJUVI? How strong is MONJUVI’s clinical and commercial performance?
• What is MONJUVI’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma and Follicular lymphoma; as well as potential indication like Marginal zone B-cell lymphoma, Autoimmune haemolytic anaemia, B-cell lymphoma, Chronic lymphocytic leukaemia, and Haematological malignancies and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MONJUVI Manufacturers?
• What are the key designations that have been granted to MONJUVI for approved and potential indications? How are they going to impact MONJUVI’s penetration in various geographies?
• What is the current and forecasted MONJUVI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of MONJUVI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to MONJUVI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is MONJUVI? What is the duration of therapy and what are the geographical variations in cost per patient?